<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Kuznar, Wayne</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Saag, Kenneth</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Lesinurad Provides Additional Lowering of SUA in Gout</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">10-10</style></pages><abstract><style  face="normal" font="default" size="100%">Current management of gout is suboptimal, and patients often do not achieve serum uric acid (SUA) targets with allopurinol monotherapy. This article discusses the results of 2 replicate phase 3 studies known as Combining Lesinurad With Allopurinol in Inadequate Responders [CLEAR 1 and CLEAR 2; NCT01510158 and NCT01493531, respectively] conducted in symptomatic adults with gout.</style></abstract><number><style face="normal" font="default" size="100%">51</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>